Needham & Company LLC Raises OrthoPediatrics (NASDAQ:KIDS) Price Target to $30.00

OrthoPediatrics (NASDAQ:KIDS) had its price objective hoisted by analysts at Needham & Company LLC from $26.00 to $30.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target would suggest a potential upside of 56.49% from the stock’s current price.

Other research analysts have also recently issued research reports about the company. TD Cowen upgraded OrthoPediatrics to a “strong-buy” rating in a research report on Tuesday, January 27th. Weiss Ratings restated a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Thursday, January 22nd. Canaccord Genuity Group started coverage on shares of OrthoPediatrics in a research report on Wednesday, December 10th. They set a “buy” rating and a $24.00 price objective for the company. Finally, Wall Street Zen downgraded shares of OrthoPediatrics from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $24.44.

OrthoPediatrics Stock Up 7.8%

Shares of KIDS opened at $19.17 on Friday. OrthoPediatrics has a one year low of $15.28 and a one year high of $26.40. The company has a market capitalization of $480.78 million, a P/E ratio of -11.34 and a beta of 1.12. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.40 and a quick ratio of 3.52. The business’s 50 day simple moving average is $17.64 and its 200-day simple moving average is $18.14.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.11. OrthoPediatrics had a negative return on equity of 6.68% and a negative net margin of 16.77%.The firm had revenue of $61.61 million for the quarter, compared to the consensus estimate of $61.27 million. As a group, sell-side analysts predict that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

Institutional Investors Weigh In On OrthoPediatrics

A number of institutional investors have recently added to or reduced their stakes in KIDS. Grandeur Peak Global Advisors LLC acquired a new position in shares of OrthoPediatrics during the second quarter worth $452,000. Los Angeles Capital Management LLC bought a new position in OrthoPediatrics during the 2nd quarter worth $220,000. Jane Street Group LLC lifted its holdings in OrthoPediatrics by 199.6% during the 4th quarter. Jane Street Group LLC now owns 132,166 shares of the company’s stock worth $2,347,000 after buying an additional 88,047 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of OrthoPediatrics by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 135,475 shares of the company’s stock valued at $2,406,000 after buying an additional 4,360 shares during the last quarter. Finally, Nantahala Capital Management LLC increased its stake in shares of OrthoPediatrics by 303.3% in the fourth quarter. Nantahala Capital Management LLC now owns 199,449 shares of the company’s stock valued at $3,542,000 after buying an additional 150,000 shares during the period. 69.05% of the stock is owned by institutional investors.

Key OrthoPediatrics News

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Q4 beat — OrthoPediatrics reported EPS of ($0.26) vs. consensus ($0.37) and revenue of $61.61M vs. $61.27M, a combination that surprised the market to the upside. Earnings Release
• Positive Sentiment: Needham raised its price target to $30 and reiterated a Buy — the new target implies material upside versus the current share level and likely supported buying interest. Benzinga
• Positive Sentiment: BTIG also raised its target to $24 and kept a Buy rating, adding further analyst support to the stock move. Benzinga
• Positive Sentiment: Company reiterated 2026 revenue guidance of $262M–$266M and described an accelerating “product innovation super‑cycle,” which management frames as a multi‑year growth driver. Seeking Alpha
• Neutral Sentiment: Investor access: OrthoPediatrics announced participation in upcoming investor conferences, which should help management communicate the growth story but is not material on its own. GlobeNewswire
• Neutral Sentiment: Analyst/media coverage and detailed call notes/transcript are circulating (earnings transcript and coverage from Yahoo, Zacks, Seeking Alpha), which helps investors parse the quarter. Yahoo Finance
• Negative Sentiment: Profitability remains a concern — OrthoPediatrics is still loss‑making (negative net margin ~20% and negative ROE), and consensus expects negative full‑year EPS, which limits valuation multiple expansion until sustained profit improvement. Zacks

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.